CHEK2突变携带者的皮肤癌风险
本文综述CHEK2突变携带者皮肤癌风险的文献。CHEK2为细胞周期调节基因,与癌症发病机制相关,但临床研究证据不一致且存在冲突。黑色素瘤方面,一项研究显示CHEK2突变个体风险统计学显著增加两倍,尤其CHEK2*1100delC变异,另五项研究未显示关联。非黑色素瘤皮肤癌数据较少。总体证据尚不足以得出确定性结论,但分子机制关联明显,建议CHEK2突变患者可从皮肤科筛查中获益。
要点
- CHEK2突变与黑色素瘤风险关联证据不一致,仅一项研究显示风险增加两倍。
- 非黑色素瘤皮肤癌数据有限,尚无CHEK2与皮肤鳞状细胞癌的研究。
- CHEK2突变患者可能从皮肤科筛查中获益,尤其关注皮肤癌。
核心结论
- 目前证据不足以就CHEK2携带者黑色素瘤和非黑色素瘤皮肤癌风险增加做出确定性结论。
- 分子机制上CHEK2突变与皮肤恶性肿瘤发病机制存在明显关联,需进一步研究。
研究设计与样本
- 本文为综述,汇总文献中关于CHEK2突变携带者黑色素瘤和非黑色素瘤皮肤癌风险的信息。
主要发现
- 一项研究显示CHEK2突变个体黑色素瘤风险统计学显著增加两倍,尤其CHEK2*1100delC变异。
- 五项其他研究未显示CHEK2突变与黑色素瘤的关联。
- 非黑色素瘤皮肤癌数据较少,仅有一项在基底细胞癌患者队列中CHEK2突变的患病率研究。
- 目前尚无CHEK2与皮肤鳞状细胞癌的研究,但其他学科数据显示CHEK2与头颈部鳞状细胞癌相关。
临床怎么用
- CHEK2突变患者可能从皮肤科筛查检查中获益,尤其关注皮肤癌。
局限性
- 临床研究证据不一致且存在冲突。
- 非黑色素瘤皮肤癌数据较少。
- 目前尚无CHEK2与皮肤鳞状细胞癌的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CHEK2 mutations have been linked with an increased risk of breast cancer. A unique challenge for oncodermatologists and oncologists is in the monitoring and counselling of patients regarding skin cancer risk due to CHEK2 mutation carrier status. In this review, we highlight current information in the literature on the risk of melanoma and non-melanoma skin cancers in CHEK2 mutation carriers. On the molecular level, CHEK2 is a cell cycle regulator that has been linked to cancer pathogenesis, though evidence from clinical studies regarding skin cancer risk has been inconsistent and conflicting. For melanoma, one study has demonstrated a statistically significant twofold risk of melanoma in individuals with CHEK2 mutations, particularly the CHEK2*1100delC variant. Five other studies did not show an association. For non-melanoma skin cancer, fewer data exist, with one prevalence study of CHEK2 mutations in a cohort of patients with basal cell carcinomas. Although there are currently no known studies of CHEK2 and cutaneous squamous cell carcinoma (SCC), data from other disciplines associating CHEK2 with head and neck SCCs are emerging. Overall, while there is currently not enough evidence to make conclusive statements regarding increased risk of melanoma and non-melanoma skin cancers in CHEK2 carriers, a molecular mechanism associating the mutation with cutaneous malignancy pathogenesis is evident, and further work is needed. Patient with CHEK2 mutations may benefit from screening dermatologic examinations with particular attention to skin cancers.
引用
- Bui AN, LeBoeuf NR, Nambudiri VE, et al. Skin cancer risk in CHEK2 mutation carriers. J Eur Acad Dermatol Venereol. 2020. PMID: 32531112. doi:10.1111/jdv.16729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。